Mechanisms of stent thrombosis: insights from optical coherence tomography

Seung-Yul Lee[1], Myeong-Ki Hong[2,3,4]

[1]Sanbon Hospital, Wonkwang University College of Medicine, Gunpo, Korea; [2]Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea; [3]Cardiovascular Research Institute, [4]Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea
Correspondence to: Myeong-Ki Hong, MD, PhD. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 03722 Yonsei-ro 50-1, Seodaemun-gu, Seoul, Korea. Email: mkhong61@yuhs.ac.

Although the improvement of coronary stents and medical agents has reduced adverse cardiac events in patients undergoing percutaneous coronary intervention (PCI), stent thrombosis (ST) still remains one of fatal complications of stent therapy. However, the pathophysiology of ST has not been sufficiently established yet, and factors including comorbidities such as diabetes mellitus, stent design, and patients' response or adherence to antiplatelet therapy have had the association with ST occurrence (1,2). Recently, a large prospective registry study investigating the intravascular morphologies of coronary stents in patients suffering from ST was published (3). Using optical coherence tomography (OCT) that had higher resolution than intravascular ultrasound, the study demonstrated the underlying mechanisms of ST, helping to guide the ST treatment (3). In this article, ST-related factors focusing on coronary stents are discussed.

Stent malapposition and under-expansion

Stent malapposition is defined as separation of at least 1 stent strut from the intimal surface of the arterial wall that is not overlapping a side branch (4). Because these floating struts are associated with delayed healing after stent implantation, especially drug-eluting stent (DES), malapposed stents have been considered as a potential risk for the development of ST. However, clinical data about stent malapposition have been controversial. In intravascular ultrasound study investigating the long-term prognosis of late stent malapposition that was detected at 6 months after DES implantation, the stent malapposition was not associated with any major adverse cardiac events during a subsequent 10-month follow-up (4). A similar finding was observed in an OCT study, in which adverse cardiac events did not occur in patients with late stent malapposition during follow-up of mean 28 months after DES implantation (5). Contrary to these studies, cross-sectional OCT studies showed that the malapposition was a leading cause of early, late, or very late ST (3,6). These discrepancies were partly explained by the finding that stent malapposition could be spontaneously resolved over time (5,7). As a determinant for the resolution of stent malapposition, the distance between malapposed strut and vessel wall was proposed: the greater the distance, the more persistent the malapposition (8). In the study by Souteyrand *et al.*, the average maximal malapposition distance was 710 μm, indicating the severe malapposition (3).

Factors causing stent malapposition are multifactorial. During stent implantation, malapposition can occur for stent under-expansion, or appear for follow-up period due to positive vascular remodeling of stented lesion. In some cases presented with acute coronary syndrome, thrombus between struts and vascular wall may spontaneously dissolve, causing the malapposition. However, the important thing here is that inadequately expanded stent during PCI can be fully preventable using intravascular imaging modalities. Until recently, it has not been determined whether the routine usage of the imaging devices for PCI is beneficial or not. Nevertheless, the usefulness of intravascular imaging seems to be robust to achieve the optimal stent expansion, and to minimize large stent malapposition. Considering

the delayed healing of malapposed stents, the finding that stent malapposition and under-expansion were prominent mechanisms for early ST is not surprising.

Neoatherosclerosis

Emerging evidences have established that neoatherosclerosis, atherogenesis within neointima of implanted coronary stent, is one of mechanisms causing late stent failure. According to the pathologic study, neoatherosclerosis was not rare, and could have unstable features such as thin cap or rupture of neointimal tissue (9). In several OCT studies, neoatherosclerosis was more identified in patients presented with acute coronary syndrome than in those with stable restenotic lesion, resulting in more target lesion revascularizations (10,11). Thus, neoatherosclerotic lesion could be manifested with wide spectrum from stable coronary artery disease to acute myocardial infarction including late or very late ST (12). This feature was also confirmed in ST registries, in which ruptured neoatherosclerosis, as well as stent malapposition, was a frequent OCT finding in patients suffering from late or very late ST (3,6). Although the pathophysiology of neoatherosclerosis has remained unknown, several OCT studies suggested that specific factors such as stent type, stent age, patients' characteristics including current smoking, chronic kidney disease, usage of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade, and the concentration of low-density lipoprotein cholesterol were associated with the presence of neoatherosclerosis at follow-up (13-15). Accordingly, the continued medical care for the inhibition of neoatherosclerosis may be warranted in patients receiving coronary stents.

Importantly, the OCT study from Souteyrand *et al.* revealed the underlying morphological abnormalities in most ST cases, introducing the possibility of patient-tailored therapy (3). For example, in ST resulting from malapposition, a simple balloon angioplasty may be sufficient to restore the coronary flow, and to attach malapposed struts to vascular wall. On the contrary, an additional stent implantation may be not beneficial without resolving the malapposition. In patients with neoatherosclerosis, a plain balloon angioplasty may be not appropriate to inhibit the future growth of neoatherosclerotic neointima. These individualized strategies, based on the mechanisms of ST occurrence, look reasonable, but it is not easy to prove the benefits of these approaches because the incidence of ST is quite low,

requiring a large study population for screening. In the 2011 ACCF/AHA/SCAI guideline for PCI, the treatments of patients presented with ST were not established, thus emphasizing the importance of ST prevention that included ensuring compliance with dual antiplatelet therapy and adequate stent sizing and expansion (16). However, given the poor prognosis of ST, it is necessary to consider the specific treatment strategy based on intravascular imaging in patients undergoing ST.

Acknowledgements

Footnote

References

1. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409.

2. Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010;122:52-61.

3. Souteyrand G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. Eur Heart J 2016;37:1208-16.

4. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113:414-9.

5. Im E, Kim BK, Ko YG, et al. Incidences, predictors, and

clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation. Circ Cardiovasc Interv 2014;7:88-96.

6. Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Circulation 2016;133:650-60.

7. Gutiérrez-Chico JL, Wykrzykowska J, Nüesch E, et al. Vascular tissue reaction to acute malapposition in human coronary arteries: sequential assessment with optical coherence tomography. Circ Cardiovasc Interv 2012;5:20-9, S1-8.

8. Kawamori H, Shite J, Shinke T, et al. Natural consequence of post-intervention stent malapposition, thrombus, tissue prolapse, and dissection assessed by optical coherence tomography at mid-term follow-up. Eur Heart J Cardiovasc Imaging 2013;14:865-75.

9. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.

10. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation 2011;123:2954-63.

11. Lee SY, Shin DH, Mintz GS, et al. Optical

coherence tomography-based evaluation of in-stent neoatherosclerosis in lesions with more than 50% neointimal cross-sectional area stenosis. EuroIntervention 2013;9:945-51.

12. Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 2012;59:2051-7.

13. Yonetsu T, Kato K, Kim SJ, et al. Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry. Circ Cardiovasc Imaging 2012;5:660-6.

14. Lee SY, Hur SH, Lee SG, et al. Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv 2015;8:e001878.

15. Kim C, Kim BK, Lee SY, et al. Incidence, clinical presentation, and predictors of early neoatherosclerosis after drug-eluting stent implantation. Am Heart J 2015;170:591-7.

16. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122.